Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients
We use cookies to improve your experience on our site, to show you personalized advertising, and as otherwise described in our Cookie Policy
. To find out more, read our
Privacy Policy
and our
Cookie Policy.